Susanne Meline - 09 Jan 2023 Form 4 Insider Report for Ra Medical Systems, Inc. (VTAK)

Role
Director
Signature
/s/ Susanne Meline
Issuer symbol
VTAK
Transactions as of
09 Jan 2023
Net transactions value
$0
Form type
4
Filing time
27 Mar 2023, 17:22:02 UTC
Previous filing
04 Jan 2023
Next filing
02 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMED Common Stock Conversion of derivative security $0 +2,575 $0.000000 2,575 23 Mar 2023 By Spouse F1
holding RMED Common Stock 36 09 Jan 2023 Direct
holding RMED Common Stock 800 09 Jan 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMED Series X Convertible Preferred Stock Award $0 +14 $0.000000 14 09 Jan 2023 Common Stock 14,056 $0.000000 By Spouse F3, F4, F5
transaction RMED Series X Convertible Preferred Stock Conversion of derivative security $0 -3 -18% $0.000000 11 23 Mar 2023 Common Stock 11,481 $0.000000 By Spouse F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This the transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.
F2 Securities are owned by Catalysis Partners ("CP"). The reporting person has an investment interest in CP through her IRA and, together with an immediate family member, owns a controlling interest in Francis Capital Management, LLC, which also has an investment interest in CP and serves as both its Managing Member and Investment Manager. The reporting person disclaims beneficial interest of these securities except to the extent of her pecuniary interest therein.
F3 Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.
F4 On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).
F5 Series X Convertible Preferred Stock has no expiration date.